术中锥形束CT联合实质血容量评估指导DEB-TACE:与单纯DSA引导的疗效比较
该回顾性单中心研究纳入179例肝细胞癌患者,比较PBV-CBCT引导与单纯DSA引导的DEB-TACE疗效,经匹配配对分析(各28例)发现两组mRECIST缓解率与总生存无显著差异,但PBV-CBCT组中位TACE次数更少(2.0 vs 3.0,p=0.046),提示其可减少再干预且不影响疗效。
要点
- PBV-CBCT引导DEB-TACE可减少再干预次数,中位TACE次数2.0 vs 3.0(p=0.046)。
- 两组mRECIST缓解率(p=0.174)与中位总生存(p=0.815)无显著差异。
- 术中获得即时反馈有助于提高治疗效率并避免不必要的再干预。
核心结论
- 术中PBV-CBCT引导DEB-TACE可减少再干预次数,且对肿瘤缓解和总生存无负面影响。
- 研究结果支持将PBV-CBCT用于DEB-TACE引导,即时反馈可提高治疗效率并避免不必要的再干预。
研究设计与样本
- 回顾性单中心研究,共纳入179例肝细胞癌患者(平均年龄77.4岁),其中PBV-CBCT组28例、单纯DSA组151例。
- 使用负载表柔比星的100-300 μm微球行DEB-TACE。
- 疗效评估基于匹配配对分析(CBCT组28例 vs DSA组28例),两组性别、肿瘤数目、肿瘤大小及HCC危险因素分布均衡。
- 记录mRECIST肿瘤缓解、总生存、TACE干预次数及肝功能和炎症实验室参数。
诊断标准与关键数值
- mRECIST缓解率:CBCT组PD 7%、SD 28%、PR 46%、CR 18%;DSA组PD 7%、SD 32%、PR 39%、CR 21%(p=0.174)。
- 中位总生存:CBCT组44.1个月,DSA组28.8个月(p=0.815)。
- 中位TACE次数:CBCT组2.0次,DSA组3.0次(p=0.046)。
临床应用与阅片要点
- 在DEB-TACE术中可考虑使用PBV-CBCT评估实质血容量,以即时判断栓塞效果并指导补充栓塞。
- PBV-CBCT引导可能减少后续不必要的TACE再干预,但需结合肿瘤缓解和生存综合评估。
局限性
- 回顾性单中心研究设计,PBV-CBCT组样本量较小(n=28)。
- 采用匹配配对分析以平衡组间基线,但样本量有限可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The objective of this retrospective single centre study was to evaluate the impact of intraprocedural cone-beam CT with parenchymal blood volume assessment (PBV-CBCT) for guidance of transarterial chemoembolization with drug-eluting beads (DEB-TACE) in HCC patients on the effectiveness (local tumour response, survival and number of individual TACE sessions) compared to guidance solely by digital subtraction angiography (DSA).
METHOD: n = 179 HCC patients (mean age, 77.4 y) undergoing DEB-TACE, with (n = 28) and without (n = 151) PBV-CBCT, using 100-300 μm microspheres loaded with epirubicin were retrospectively analysed. Tumour response according to mRECIST, overall survival and number of TACE interventions as well as laboratory parameters for liver function and inflammation were recorded. The analysis of the influence of intraprocedural PBV-CBCT was based on matched pair analysis (CBCT n = 28 vs. DSA n = 28). Gender, tumour number, tumour size and HCC risk factors were equally distributed between both groups.
RESULTS: Response rates according to mRECIST:CBCT: PD: 7%, SD: 28 %, PR: 46 %, CR: 18 %; DSA: PD: 7 %, SD: 32 %, PR: 39 %, CR: 21 % (p = 0.174). Median OS: CBCT: 44.1 months; DSA: 28.8 months (p = 0.815). Median TACE number: CBCT: 2.0; DSA: 3.0 (p = 0.046).
CONCLUSIONS: The use of intraprocedural PBV-CBCT for TACE guidance reduced the number of re-interventions, with no negative effects on tumour response and overall survival. The study findings support the use of PBV-CBCT for DEB-TACE guidance as the improved immediate feedback leads to a considerable increase of the treatment efficiency and helps to avoid unnecessary re-interventions.
引用
- Peisen F, Maurer M, Grosse U, et al. Intraprocedural cone-beam CT with parenchymal blood volume assessment for transarterial chemoembolization guidance: Impact on the effectiveness of the individual TACE sessions compared to DSA guidance alone. Eur J Radiol. 2021. PMID: 33991970. doi:10.1016/j.ejrad.2021.109768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。